尊龙凯时·[中国]官方网站

The first generic drug consistency evalsuation in China

- A new generation of selective ergot dopamine receptor agonists;

- It is recommended as first-line medication for early Parkinson’s treatment by the United States, European and Chinese Parkinson's guidelines.

- Its efficacy and safety are demonstrated by over-20-year clinical medication experience abroad.

- The incidence of dyskinesia in early Parkinson's patients is very low, and it can significantly delay the onset of dyskinesia.

-It assists L-dopa in the treatment of patients with advanced Parkinson’s disease. It can effectively shorten the “day off phenomenon” and reduce 20% of the usage amount of L-dopa.